1. Home
  2. MYGN vs KROS Comparison

MYGN vs KROS Comparison

Compare MYGN & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • KROS
  • Stock Information
  • Founded
  • MYGN 1991
  • KROS 2015
  • Country
  • MYGN United States
  • KROS United States
  • Employees
  • MYGN N/A
  • KROS N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • KROS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MYGN Health Care
  • KROS Health Care
  • Exchange
  • MYGN Nasdaq
  • KROS Nasdaq
  • Market Cap
  • MYGN 2.0B
  • KROS 1.8B
  • IPO Year
  • MYGN 1995
  • KROS 2020
  • Fundamental
  • Price
  • MYGN $16.17
  • KROS $64.88
  • Analyst Decision
  • MYGN Buy
  • KROS Strong Buy
  • Analyst Count
  • MYGN 12
  • KROS 8
  • Target Price
  • MYGN $27.64
  • KROS $91.43
  • AVG Volume (30 Days)
  • MYGN 864.7K
  • KROS 360.6K
  • Earning Date
  • MYGN 11-07-2024
  • KROS 11-06-2024
  • Dividend Yield
  • MYGN N/A
  • KROS N/A
  • EPS Growth
  • MYGN N/A
  • KROS N/A
  • EPS
  • MYGN N/A
  • KROS N/A
  • Revenue
  • MYGN $823,600,000.00
  • KROS $651,000.00
  • Revenue This Year
  • MYGN $13.85
  • KROS $1,232.45
  • Revenue Next Year
  • MYGN $7.73
  • KROS $126.39
  • P/E Ratio
  • MYGN N/A
  • KROS N/A
  • Revenue Growth
  • MYGN 12.15
  • KROS 8037.50
  • 52 Week Low
  • MYGN $16.23
  • KROS $27.31
  • 52 Week High
  • MYGN $29.30
  • KROS $73.00
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 18.30
  • KROS 59.88
  • Support Level
  • MYGN $16.86
  • KROS $65.54
  • Resistance Level
  • MYGN $19.60
  • KROS $70.26
  • Average True Range (ATR)
  • MYGN 1.16
  • KROS 2.67
  • MACD
  • MYGN -0.32
  • KROS 0.52
  • Stochastic Oscillator
  • MYGN 0.37
  • KROS 57.74

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: